# Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

> **NCT06880276** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** 1.5% QLM3003 ointment
- **DRUG:** 2% QLM3003 ointment
- **DRUG:** QLM3003 Placebo

## Key facts

- **NCT ID:** NCT06880276
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2027-03
- **Final completion:** 2027-05
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880276, "Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06880276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*